Griffin, M.D., Hong, D.K., Holman, P.O., Lee, K.M., Whitters, M.J., O’Herrin, S.M., Fallarino, F., Collins, M., Segal, D.M., Gajewski, T.F., Kranz, D.M. and Bluestone, J.A. (2000) Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). Journal of Immunology, 164, 4433-4442. - References

Journals by Subject

Publish with us

Follow SCIRP

	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Article citationsMore>>

Griffin, M.D., Hong, D.K., Holman, P.O., Lee, K.M., Whitters, M.J., O’Herrin, S.M., Fallarino, F., Collins, M., Segal, D.M., Gajewski, T.F., Kranz, D.M. and Bluestone, J.A. (2000) Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). Journal of Immunology, 164, 4433-4442.

has been cited by the following article:

TITLE: New era in cancer immunotherapy: Twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors

AUTHORS: Britta Hardy, Annat Raiter

KEYWORDS: Cancer Immunotherapy; Monoclonal Antibodies; Anergy; T Cell Receptors

JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.4A, April 29, 2013

ABSTRACT: The better understanding of the mechanism in which the immune system responds to the developing cancer provided the outcome in a new era in cancer immunotherapy. The tumor suppressive effect on the immune system is caused by negative T cell receptor signaling that abrogate immunity against the cancer cells. Novel monoclonal antibodies that target co-inhibitory receptors on T cells block the tumor induced inhibition of the immune system and enable the immune system to eradicate the tumors. The development of such antibodies started twenty years ago by the preparation of a monoclonal antibody termed BAT. A single administration of the antibody to tumor bearing mice resulted in striking anti tumor activity that was mediated by the lymphocytes. These studies provided a basis for the new era of cancer immunotherapy. The present review summarizes twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors.

Open Access

Articles

Diabetic Ketoacidosis in Type 1 DM: A Novel Presentation of CML

Kory Jaggon, Spyridon Ntelis, Rediet Tefera Atalay, Girma Moges Ayele, Miriam Michael

Case Reports in Clinical Medicine Vol.11 No.9, September 15, 2022

DOI: 10.4236/crcm.2022.119051
Open Access

Articles

A Case of Euglycemic Diabetic Ketoacidosis in Patient with Type 2 DM

Lamiz Tannouri, Shahinaz Gouda, Youssef Abboud

Open Journal of Emergency Medicine Vol.11 No.4, November 8, 2023

DOI: 10.4236/ojem.2023.114017
Open Access

Articles

Mathematical Model of HIV-1 Dynamics with T Cell Activation

Obias Mulenga Chimbola

Journal of Applied Mathematics and Physics Vol.8 No.7, July 22, 2020

DOI: 10.4236/jamp.2020.87102
Open Access

Articles

DM-L Based Feature Extraction and Classifier Ensemble for Object Recognition

Hamayun A. Khan

Journal of Signal and Information Processing Vol.9 No.2, May 31, 2018

DOI: 10.4236/jsip.2018.92006
Open Access

Articles

SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM

Rushi Patel, Terry Oroszi

Pharmacology & Pharmacy Vol.15 No.12, December 30, 2024

DOI: 10.4236/pp.2024.1512027

Follow SCIRP

	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals by Subject

Publish with us

Article citationsMore>>

Home

About SCIRP

Service

Policies